Navigate the Sarepta Therapeutics $SRPT pagesFormerly AVI BioPharma $AVII
Introduction Webcasts and Events Stock Analysis and Reporting Eteplirsen Info Media Reports and Patient Testimonials Scientific and Medical Presentations DMD and Competition Infectious Disease Pipeline Get first-hand perspective and education information from an inspiring family with two boys with DMD, plus learn how you can make a difference - visit www.DMDHero.com |
|
Stock Analysis and Reporting
Here is a collection of viewpoints, summaries, and opinions on eteplirsen, Sarepta Therapeutics' $SRPT therapy in development for Duchenne Muscular Dystrophy. Note that my links are not an endorsement of any particular opinion or perspective:
For older stories, continue on to the SRPT stock analysis archive page.
- 12/16/2012 "Sarepta Therapeutics: No Problem With Cash" (SeekingAlpha)
- 11/27/2012 message board musings about COGS, pricing, market size, valuation.
- 12/10/2012 "Sarepta Is Still A Buy: Recent Concerns Much Ado About Nothing" (The Street/Nate S-N)
- 1/11/2013 "Sarepta May Seek Partnership Advice for Experimental Drug" (Bloomberg)
- 1/28/2013 "Sarepta Recovers Lost Ground With Bullish Analyst Activity" (SeekingAlpha)
- 1/31/2013 "Sarepta stock slow to recover after Twitter hoax" (Boston Business Journal)
- 1/31/2013 "Sarepta Therapeutics setting up for another move upwards" (SeekingAlpha)
- 2/12/2013 "Sarepta Will Defy Wall St. Consensus With Eteplirsen Early FDA Filing" (TheStreet)
- 2/27/2013 "Glaxo DMD Drug Tied to Serious Side Effects, Hospitalizations" (TheStreet)
- 2/27/2013 "Sarepta spikes on disputed report of adverse events for rival GSK drug" (FierceBiotech)
- 3/4/2013 "Another Reason to Own Sarepta Therapeutics; Chart Indicates Continued Strength" (PropThink)
- 3/6/2013 "Don’t Miss the Forest for the Trees, Sarepta is a Top Biotech Investment" (PropThink)
- 3/8/2013 "PROFITING ON THE POSSIBILITY THAT THE FDA HAS TURNED A NEW LEAF" (LittleBear)
- 3/19/2013 "DB Analyst Gets It: Sarepta Is a Winner Even Without Accelerated Approval" (TheStreet)
- 3/23/2013 "A Critical Moment for Sarepta" (Barrons)
- 3/28/2013 "Sarepta Therapeutics' Eteplirsen Trial: A Closer Look Reveals Clinical Uncertainty" (SeekingAlpha)
- 4/2/2013 "New-look Sarepta eyes approval for muscular dystrophy drug" (Reuters)
- 4/9/2013 "Hey Sarepta Investors: Glaxo's Drisapersen Data Revealed Early" (TheStreet)
- 4/9/2013 "Sarepta approach validated by Prosensa data, says Leerink" (TheFlyOnTheWall)
- 4/9/2013 "Deutsche Bank: Study Helps Validates Sarepta Therapeutic's (SRPT) Technology" (BusinessInsider)
- 4/10/2013 "Glaxo Muscular Dystrophy Drug Reaches Primary Objective in Study" (Bloomberg)
- 4/10/2013 "Sarepta overheats in a clash of the Duchenne titans" (EP Vantage)
- 4/10/2013 "Data from the Closest Competition, It Turns Out, Support Sarepta" (PropThink)
- 4/11/2013 "Sarepta Wants to Change the Way We Do Business with the FDA" (RDR)
- 4/11/2013 "GlaxoSmithKline measures 36-meter leap over placebo in Duchenne walking test" (FierceBiotech)
- 4/12/2013 "Sarepta Fans: A Single Data Slide Raises Questions About Glaxo's DMD Drug" (TheStreet)
For older stories, continue on to the SRPT stock analysis archive page.